<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606694</url>
  </required_header>
  <id_info>
    <org_study_id>DHM-Metformin-T2DM</org_study_id>
    <nct_id>NCT03606694</nct_id>
  </id_info>
  <brief_title>Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effect of Dihydromirycetin Administration on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dihydromyricetin has demonstrated promising effects in glycemic control, insulin sensitivity&#xD;
      and insulin secretion, that above mentioned findings show that dihydromyricetin has an&#xD;
      excellent potential effect in the treatment of type 2 diabetes mellitus patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized clinical trial of three pharmacological groups in 36 patients with&#xD;
      a diagnosis of type 2 diabetes mellitus in accordance with the American Diabetes Association&#xD;
      (ADA) without treatment.&#xD;
&#xD;
      They will be assigned randomly two groups of 12 patients, each one will receive&#xD;
      dihydromyricetin 300 mg or metformin 850 mg, two times per day before having break-fast and&#xD;
      before having dinner during 12 weeks.&#xD;
&#xD;
      The Area Under the Curve of glucose and insulin will be calculated, total insulin secretion&#xD;
      (Insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin&#xD;
      sensitivity (Matsuda index).&#xD;
&#xD;
      This protocol is already approved by the local ethics committee and written informed consent&#xD;
      it's going to be obtained from all volunteers.&#xD;
&#xD;
      Statistical analysis will be presented through measures of central tendency and dispersion,&#xD;
      average and deviation standard for quantitative variables; frequencies and percentages for&#xD;
      variable qualitative. Qualitative variables will be analyzed by X2, will be used for&#xD;
      differences inter-group Mann-Whitney U Test and Wilcoxon Test for the within-groups&#xD;
      differences. It will be considered statistical significance p â‰¤0.05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Changes in fasting glucose levels after 12 weeks of intervention with dihydromyricetin and metformin. The fasting glucose levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial glucose</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Changes in postprandial glucose levels after 12 weeks of intervention with dihydromyricetin and metformin. Postprandial glucose will be evaluated at baseline and week 12 after a oral glucose tolerance test with enzymatic/colorimetric techniques and the entered values reflect the insulin sensitivity at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycosylated hemoglobin</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Changes in glycosylated hemoglobin (A1C) after 12 weeks of intervention with dihydromyricetin and metformin. Glycosylated hemoglobin will be evaluated at baseline and week 12 by high pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Insulin sensitivity will be calculated at baseline and week 12 with Matsuda index and the entered values reflect the insulin sensitivity at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total insulin secretion</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Total insulin secretion will be calculated at baseline and week 12 with insulinogenic index and the entered values reflect the total insulin secretion at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First phase of insulin secretion</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The first phase of insulin secretion will be calculated at baseline and week 12 with Stumvoll index and the entered values reflect the first phase of insulin secretion at week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Waist circumference will be evaluated at baseline and at week 12 with a flexible tape.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weigh</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>The body weight will be measured at baseline, week 4, week 8 and week 12 with a bioimpedance balance and the entered values reflect the body weight at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Body Mas Index will be calculated at baseline, week 4, week 8 and week 12 with the Quetelet index formula and the entered values reflect the body mass index at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C reactive protein</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>C reactive protein will be evaluated at baseline and week 12 by enzyme-linked immunosorbent assay (ELISA) and the entered values reflect the creatinine levels at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Interleukin 6 will be evaluated at the beginning and during week 12 using the enzyme-linked immunosorbent assay (ELISA) and the values entered reflect creatinine levels at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Total cholesterol levels will be evaluated at baseline and week 12 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Triglycerides levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein (c-HDL) levels</measure>
    <time_frame>Basline to Week 12</time_frame>
    <description>c-HDL levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoproteins (c-LDL) levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>c-LDL levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Creatinine levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase (ALT) levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>ALT levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase (AST) levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>AST levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Blood pressure will be measured at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dihydromyricetin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dihydromyricetin capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydromyricetin</intervention_name>
    <description>The intervention wiil be 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
    <arm_group_label>Dihydromyricetin</arm_group_label>
    <other_name>Ampelopsis grossedentata Extract</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>The intervention wiil be 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Brad Predial</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients both sexes&#xD;
&#xD;
          -  Age between 30 and 60 years&#xD;
&#xD;
          -  Diabetes mellitus type 2 of recent diagnosis without pharmacological treatment, with&#xD;
             one of the following criteria (fasting blood glucose levels &gt;126 mg/dL; postprandial&#xD;
             blood glucose levels after an oral glucose tolerance test with 75 of oral glucose &gt;200&#xD;
             mg/dl; or glycosylated hemoglobin between &gt;6.5%)&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with confirmed or suspected pregnancy, or under lactation and/or puerperium&#xD;
&#xD;
          -  Previous treatment for glucose&#xD;
&#xD;
          -  Fasting glucose â‰¥250 mg/dL&#xD;
&#xD;
          -  Body Mass Index â‰¥34.9 kg/m2&#xD;
&#xD;
          -  Known uncontrolled renal, hepatic, heart or thyroid diseased&#xD;
&#xD;
          -  Hypersensibility to ingredients of intervention&#xD;
&#xD;
          -  Triglycerides â‰¥500 mg/dL&#xD;
&#xD;
          -  Total cholesterol â‰¥240 mg/dL&#xD;
&#xD;
          -  Blood Pressure â‰¥140/90 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MANUEL GONZALEZ ORTIZ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de TerapeÃºtica Experimental y ClÃ­nica. Universidad de Guadalajara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MANUEL GONZALEZ ORTIZ, PhD</last_name>
    <phone>+523310585200</phone>
    <phone_ext>34212</phone_ext>
    <email>uiec@prodigy.net.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>KARINA PEREZ RUBIO, PhD</last_name>
    <phone>+523310585200</phone>
    <phone_ext>34212</phone_ext>
    <email>karina2410@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de TerapeÃºtica Experimental y ClÃ­nica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MANUEL GONZAEZ, PhD</last_name>
      <phone>+523310585200</phone>
      <phone_ext>34212</phone_ext>
      <email>uiec@prodigy.net.mx</email>
    </contact>
    <contact_backup>
      <last_name>KARINA PEREZ RUBIO, PhD</last_name>
      <phone>+523310585200</phone>
      <phone_ext>34212</phone_ext>
      <email>karina2410@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Karina Griselda PÃ©rez Rubio</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>dihydromyricetin</keyword>
  <keyword>metformin</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

